PLASMA DISPOSITION OF PROCHLORPERAZINE AND GENDER AFFECT ITS ANTIEMETIC EFFECT AND PROLACTIN SECRETION IN CANCER PAIN PATIENTS TREATED WITH OXYCODONE
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: TASHIRO, Masaki (Hamamatsu University Hospital, Hospital Pharmacy, Hamamatsu, Japan)
- Co-author(s): Masaki Tashiro
Prochlorperazine (PCPZ), a dopamine receptor D2 antagonist, is used for the antiemetic treatment of opioid-induced nausea and vomiting. Few clinical reports have been published on the interindividual variations in the clinical responses to PCPZ in opioid analgesics treated cancer patients.
Sixty-one cancer pain patients receiving PCPZ concomitantly.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.